Objectives: To characterise management of suspected acute coronary syndrome (ACS) in Australia and New Zealand, and to assess the application of recommended therapies according to published guidelines.
D
espite well developed guidelines for managing acute coronary syndrome (ACS), 1-6 local registries in Australia and New Zealand have demonstrated incomplete implementation of evidence-based recommendations, [7] [8] [9] [10] with variations in care appearing to correlate with differences in clinical outcomes. Geographical challenges, patient characteristics (including cultural diversity), health workforce and the health policy environment are likely factors affecting the optimal translation of this evidence base into timely, effective and riskappropriate ACS care. 11, 12 Audits of hospitalisation for ACS in New Zealand have been crucial in defi ning treatment and resource gaps in practice. 9, 13 In Australia, registries have included relatively few patients from regional and remote centres. 7 However, health service design and workforce provision have been found to be associated with variations in clinical outcomes in Australia.
14 Hence, gaining a bi national perspective from multiple health services of current ACS management is an essential step in health services redesign. The SNAPSHOT ACS study sought to inform these efforts by documenting care and outcomes among patients with suspected ACS through a comprehensive audit encompassing all hospitals and jurisdictions in Australia and New Zealand.
Methods

Study design and organisation
The SNAPSHOT ACS study was a prospective audit of the care provided to consecutive patients admitted with suspected ACS during a 2-week period in Australia and New Zealand. The study was designed by a binational academic network of clinicians and researchers, and managed by a steering committee with key stakeholder representation. It was developed as a collaborative quality improvement initiative between the Cardiac Society of Australia and New Zealand, the Heart Foundation of Australia, the Australian Commission on Safety and Quality in Health Care, the George Institute for Global Health, and health networks or state governments in New South Wales, Queensland, Victoria, South Australia and Western Australia (Appendix 1; all appendices are online at mja.com.au). The national organisations provided endorsement, in-kind resources and seed funding for central study management. State governments and health networks provided study coordinators to engage facilities, educate staff and assist with gaining ethics committee approval and data collection. The George Institute built the online database and coordinated data management.
All hospitals (public or private, metropolitan or rural) receiving patients with suspected ACS were identifi ed through public records and health networks and approached about participating. Although sites were given training and support with data entry, each hospital's participation was discretionary and resourced locally. Written study protocols were provided to all participating sites, and state-based education forums were held to standardise recruitment and data collection. Results were fed back to each site, benchmarked against the relevant state or territory and national aggregate at the end of the audit.
In Australia, ethics approval for optout consent was granted in all but two sites in Victoria, where opt-in consent was implemented. In New Zealand, expedited review by the National Multicentre Ethics Committee concluded that this was an audit of health service delivery, and a consent waiver was applied. In Australia, a consent waiver was applied to all inhospital deaths among patients with suspected ACS.
Patient eligibility and classifi cation
Patients were eligible for inclusion if they were admitted for suspected or confi rmed ACS between 14 and 27 May 2012 (inclusive). Consecutive fi rst admissions within the audit window were included. Patients were tracked for the duration of the acute care episode, including all transfers between hospitals.
Patients were classifi ed by primary discharge diagnosis into the following groups:
• ST-segment-elevation myocardial infarction/left bundle branch block (STEMI/LBBB): patients with STsegment elevation or LBBB on an electrocardiogram (ECG) at any time during the admission, with elevation of cardiac biomarkers (except where the patient died before biomarkers were measured).
• Non-STEMI (NSTEMI): patients with evidence of biomarker elevation, with or without ECG changes consistent with ischaemia.
• Unstable angina: recorded separately but combined with "likely ischaemic chest pain" for analysis.
• Likely ischaemic chest pain: patients for whom the diagnosis remained uncertain in the absence of definitive ECG changes and/or biomarker elevation, but who received inhospital coronary revascularisation with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
• Unlikely ischaemic chest pain: extracted from the medical record, reflecting local clinician determination.
• Other diagnosis: patients for whom a clear alternative primary diagnosis emerged, or where evidence of myonecrosis was considered secondary to another disease process (eg, pulmonary embolus). 
Statistical analysis
Patient demographic and clinical characteristics, and rates of interhospital transfer, investigations, invasive procedures, provision of guidelinerecommended therapies to patients surviving to hospital discharge, and inhospital events are presented as standard descriptive statistics stratifi ed by discharge diagnosis, Australian Institute of Health and Welfare hospital classifi cation, and health jurisdiction (Australian states or territories and New Zealand). 4, 5 Due to small sample sizes, the two tiers of medium regional hospital classifi cation were combined, as were the other smaller hospital classifi cations. Private hospitals were considered as a separate group. These criteria were also applied to New Zealand hospitals. For stratification by jurisdiction, the Australian Capital Territory was combined with NSW, and Tasmania with the Northern Territory.
Dichotomous variables are reported as numbers and percentages and compared using the χ 2 test. Continuous variables are reported as medians and interquartile ranges (IQRs) and compared using the Kruskal-Wallis test.
Propensity score-adjusted estimates of the infl uence of hospital classifi cation and health jurisdiction on provision of angiography, provision of four or fi ve guideline-recommended medications at discharge, referral to cardiac rehabilitation, and major adverse cardiac events (MACE) were generated using logistic regression modelling, stratifi ed by discharge diagnosis. Assessment of angiography and MACE used all patients, while evaluation of rehab ilitation referral and discharge medications was confi ned to patients with a discharge diagnosis of ACS. Propensity scores using age, sex, GRACE score, diagnostic group, 
Defi nitions of inhospital events
Inhospital mortality: included any-cause mortality New or recurrent myocardial infarction (MI): recurrent chest pain lasting у 30 minutes and у 2 mm of ST-segment elevation within 18 hours of presentation, the development of a new left bundle branch block pattern or new Q waves or the following biomarker patterns: a rise in creatine kinase (CK) level to > 2 upper reference limit (URL) and > 50% above previous baseline level; or CK-MB > 50% above prior level or troponin > 20% above previous baseline level New MI after percutaneous coronary intervention: a rise in CK, CK-MB or troponin level to > 3 URL if not previously elevated, or > 50% and > 20% rise above previous levels of CK-MB and troponin, respectively, if previously elevated New MI after coronary artery bypass grafting: a rise in CK or CK-MB level to > 10 and > 5 URL, respectively, if not previously elevated, or a > 50% rise above previous level if elevated, or a 10-fold elevation in troponin level Major adverse cardiac event: the occurrence of any one of the above events  heart failure at presentation, renal impairment, diabetes, hypertension, nursing home residence, dementia or cognitive impairment, private insurance, and primary language other than English were constructed for the likelihood of living in each jurisdiction and presenting to a hospital of each classifi cation. Each model included the hospital classifi cations and jurisdictions as indicator variables, as well as their respective propensity scores, when reporting the jurisdiction or hospital estimates. Interaction terms of each jurisdiction and hospital classifi cation were explored for signifi cance, but no interactions were found. Given the observational and hypothesis-generating nature of these analyses, no adjustment of signifi cance levels was undertaken.
Analyses were performed using Stata 11.2 (StataCorp), and P < 0.05 was considered statistically signifi cant.
Results
Participating hospitals
Of 525 hospitals approached to participate, 478 gained ethics approval, and 435 provided site survey data describing their local resources. Within the 2-week enrolment period, 286 hospitals enrolled 4398 patients with suspected or confi rmed ACS. Hospitals not enrolling patients were smaller centres and did not treat patients with suspected ACS during the audit window.
Most patients (65.7%; 2891/4398) presented to principal referral hospitals or hospitals in major cities (7.7%; 337/4398), while 7.3% (319/4398) presented to private hospitals. In terms of cardiac services available at the fi rst presenting hospital, 79.7% of patients (3415/4283) presented where fi brinolysis could be administered, and 59.0% (2528/4283) presented to hospitals capable of providing primary PCI. Only 1.4% of patients (59/4283) presented to hospitals with no reperfusion therapy for STEMI. A quarter of patients (25.9%; 1138/4398) required transfer to at least one other hospital.
The distribution of hospital types by jurisdiction was comparable, except for Victoria, where a selective hospital recruitment strategy operated and there were fewer small regional hospitals (Box 2). Patient characteristics by health jurisdiction and hospital classifi cation are presented in Appendix 2 and Appendix 3, respectively.
Patients with ACS
The risk profi le of enrolled patients was high, with a median GRACE risk score of 119 (IQR, across the entire population, and 138 (IQR, 114-161) among those with a discharge diagnosis of myocardial infarction (MI), including STEMI and NSTEMI.
Of the 4398 patients, 252 (5.7%) were Indigenous, Pacifi c Islander or Maori, and 165 (3.8%) were Asian. A primary language other than English was spoken by 294 patients (6.7%). Patient characteristics by discharge diagnosis are shown in Box 3. Among the 837 patients who were discharged with a diagnosis other than ACS, 317 (37.9%) had a troponin level above the local upper reference limit.
Provision of ACS care
Among Guideline-recommended investigations and therapies were provided less frequently to patients presenting to non-principal referral hospitals, regardless of patient transfers (Box 4). Similar heterogeneity in the provision of care was observed when the results were stratifi ed by jurisdiction (Appendix 4). Variation in the timeliness of care was also evident across jurisdictions; this was most marked in the median time to angiography and, to a lesser extent, in the overall length of stay (Appendix 5).
Inhospital events
Among the patients diagnosed with MI, the inhospital mortality rate was 4.5% (65/1436) and recurrent MI rate was 5.1% (73/1436). Inhospital adverse clinical events were highest among patients with STEMI/LBBB (Box 5). Inhospital mortality and recurrent cardiac failure were frequent among patients discharged with a diagnosis thought not to be ACS. Box 6 shows substantial heterogeneity in clinical events between hospital classifi cations, in all patients and in those discharged with a diagnosis of ACS.
Adjusted analyses
The propensity-adjusted odds ratios and confi dence intervals describing the likelihood of undergoing inpatient angiography, receiving four or fi ve guideline-recommended medications at discharge, receiving referral to rehabilitation, and experiencing inhospital MACE are shown in Box 7. There was a consistently lower likelihood of receiving guideline-recommended medications among patients originally presenting to non-principal referral hospitals. Patients in private hospitals were signifi cantly more likely to undergo angiography, but not necessarily to receive guideline-recommended medications or rehabilitation referral. There was more variation in the occurrence of inhospital MACE at the health jurisdiction level than between hospital types.
Discussion
Optimising patient outcomes after MI through standardisation of care has emerged as a major near-term goal in the health agenda of Australia and New Zealand. 17 Through the most representative assessment of ACS health service resources, clinical care provision and outcomes yet conducted in Australasia, this study provides unique insights into the challenges of providing timely and effective ACS care. These include the complexity of patient comorbidities, which brings the logistical challenges of providing timely invasive management to many patients in regional, remote and outer metropolitan centres into sharp focus.
11,12
Translating evidence into practice requires a sophisticated understanding of determinants of care provision at the patient, clinical service and health policy level. Variations in clinical decision making, service availability and health policy represent potential targets for improving translation of the ACS evidence base and outcomes. An integrated approach to health service design is paramount to meeting the needs of our culturally diverse and geographically dispersed communities.
The efficient management of patients presenting with suspected 18 This is demonstrated in our study by the substantial proportion of patients with suspected ACS who had elevated troponin levels, but in whom further investigations confi rmed a fi nal diagnosis other than ACS. 19, 20 Nevertheless, our data demonstrate high rates of inhospital events among such patients, as has been observed by others; 21 ,22 yet the current evidence informing their management is very limited.
Similarly, our data demonstrate the substantial burden of clinical complexity among ACS patients, with relatively high prevalences of comorbidities including prior major bleeding events, cerebrovascular disease, cognitive impairment and concurrent malignancy.
23 This complexity underscores the everyday challenges in applying the evidence among patients with typical ACS presentations. Reduced application of evidence-based therapies among patients with increased comorbidities has been found in other studies. 24, 25 Objective risk stratifi cation that balances the benefi ts of evidence-based therapies against the risks associated with comorbidities may help narrow the evidence-practice gap for ACS patients with comorbidities.
26
Our study highlights the potential for variation in care attributable to jurisdictional and geographical differences. The challenge of providing timely access to invasive management, not only in rural areas but also in the growing outer suburbs of cities, is highlighted by the fact that 26% of 4 Provision of (A) investigations and revascularisation and (B) guideline-recommended therapies, among patients with a discharge diagnosis of acute coronary syndrome, by enrolling hospital classifi cation* all ACS patients in our study required transfer. Attempts to improve consistency and quality of care, such as through clinical guidelines and clinical standards, 17 need to consider the signifi cant issues of transfer and coordination of care, particularly outside metropolitan areas, if such initiatives are to be effective and cost-effective.
In combination, these observations call for judicious and validated approaches to the development and implementation of clinical standards and performance measures that take these diagnostic and therapeutic complexities into account.
The broad hospital recruitment approach, consecutive patient enrolment, and high inhospital event rates in our study underscore the importance of representative patient inclusion when evaluating practice and outcomes. 27 For the effective integration of clinical guidelines, clinical standards and performance measures into everyday care, the real challenge is to develop mechanisms to acquire and feed back such data on a routine and sustainable basis. 28 The SNAPSHOT ACS study was the culmination of signifi cant efforts to engage with national agencies and professional bodies, while implementation depended on the jurisdictional health networks. However, the study also required local hospital commitment to data collection and entry, an enormous unresourced effort that is diffi cult to quantify but attests to the dedication of health care providers to the quality of ACS care and outcomes. Future attempts to understand the lingering evidence-practice gaps will need to consider such resourcing issues carefully. Nevertheless, this study is unique in its ability to gain insights into the provision of care across multiple levels of decision making. Effectively 7 Adjusted odds ratios* for likelihood of (A) provision of angiography, (B) provision of four or fi ve guideline-recommended medications at discharge, (C) referral to cardiac rehabilitation, and (D) inhospital major adverse cardiac events, by hospital classifi cation and health jurisdiction delivering these insights to key decisionmakers at clinical, health service and health policy levels to enable the design and implementation of fully integrated approaches to ACS care remains the "translational" promise of this initiative.
